Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50-75 years: a phase 1/2, open-label, randomised trial.
Hsu D, Jayaraman A, Pucci A, Joshi R, Mancini K, Chen HL, Koslovsky K, Mao X, Choi A, Henry C, Vakil J, Stadlbauer D, Jorquera P, Arunkumar GA, Sanchez-Crespo NE, Wadsworth LT, Bhupathy V, Du E, Avanesov A, Ananworanich J, Nachbagauer R. Hsu D, et al. Among authors: stadlbauer d. Lancet Infect Dis. 2024 Sep 5:S1473-3099(24)00493-6. doi: 10.1016/S1473-3099(24)00493-6. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39245055
Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1/2 Randomized Trial.
Ananworanich J, Lee IT, Ensz D, Carmona L, Schaefers K, Avanesov A, Stadlbauer D, Choi A, Pucci A, McGrath S, Kuo HH, Henry C, Chen R, Huang W, Nachbagauer R, Paris R. Ananworanich J, et al. Among authors: stadlbauer d. J Infect Dis. 2024 Jun 27:jiae329. doi: 10.1093/infdis/jiae329. Online ahead of print. J Infect Dis. 2024. PMID: 38934845
Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis.
Lee IT, Nachbagauer R, Ensz D, Schwartz H, Carmona L, Schaefers K, Avanesov A, Stadlbauer D, Henry C, Chen R, Huang W, Schrempp DR, Ananworanich J, Paris R. Lee IT, et al. Among authors: stadlbauer d. Nat Commun. 2023 Jun 19;14(1):3631. doi: 10.1038/s41467-023-39376-7. Nat Commun. 2023. PMID: 37336877 Free PMC article. Clinical Trial.
Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates.
Mucker EM, Freyn AW, Bixler SL, Cizmeci D, Atyeo C, Earl PL, Natarajan H, Santos G, Frey TR, Levin RH, Meni A, Arunkumar GA, Stadlbauer D, Jorquera PA, Bennett H, Johnson JC, Hardcastle K, Americo JL, Cotter CA, Koehler JW, Davis CI, Shamblin JD, Ostrowski K, Raymond JL, Ricks KM, Carfi A, Yu WH, Sullivan NJ, Moss B, Alter G, Hooper JW. Mucker EM, et al. Among authors: stadlbauer d. Cell. 2024 Oct 3;187(20):5540-5553.e10. doi: 10.1016/j.cell.2024.08.043. Epub 2024 Sep 4. Cell. 2024. PMID: 39236707 Free article.
SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020-2023.
Carreño JM, Wagner AL, Monahan B, Singh G, Floda D, Gonzalez-Reiche AS, Tcheou J, Raskin A, Bielak D, Morris S, Fried M, Yellin T, Sullivan L; PARIS study group; Sordillo EM, Gordon A, van Bakel H, Simon V, Krammer F. Carreño JM, et al. Nat Commun. 2024 Jul 11;15(1):5847. doi: 10.1038/s41467-024-50052-2. Nat Commun. 2024. PMID: 38992013 Free PMC article.
Humoral correlates of protection against influenza A H3N2 virus infection.
Hoy G, Stadlbauer D, Balmaseda A, Kuan G, López R, Carreno Quiroz JM, Ojeda S, Sánchez N, Yellin T, Plazaola M, Frutos A, Krammer F, Gordon A. Hoy G, et al. Among authors: stadlbauer d. J Infect Dis. 2024 May 9:jiae258. doi: 10.1093/infdis/jiae258. Online ahead of print. J Infect Dis. 2024. PMID: 38723107
SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase.
Srivastava K, Carreño JM, Gleason C, Monahan B, Singh G, Abbad A, Tcheou J, Raskin A, Kleiner G, van Bakel H, Sordillo EM; PARIS Study Group; Krammer F, Simon V. Srivastava K, et al. Immunity. 2024 Mar 12;57(3):587-599.e4. doi: 10.1016/j.immuni.2024.01.017. Epub 2024 Feb 22. Immunity. 2024. PMID: 38395697 Free PMC article.
IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition.
Haslund-Gourley BS, Woloszczuk K, Hou J, Connors J, Cusimano G, Bell M, Taramangalam B, Fourati S, Mege N, Bernui M, Altman MC, Krammer F, van Bakel H; IMPACC Network; Maecker HT, Rouphael N, Diray-Arce J, Wigdahl B, Kutzler MA, Cairns CB, Haddad EK, Comunale MA. Haslund-Gourley BS, et al. Nat Commun. 2024 Jan 9;15(1):404. doi: 10.1038/s41467-023-44211-0. Nat Commun. 2024. PMID: 38195739 Free PMC article.
Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study.
Ozonoff A, Jayavelu ND, Liu S, Melamed E, Milliren CE, Qi J, Geng LN, McComsey GA, Cairns CB, Baden LR, Schaenman J, Shaw AC, Samaha H, Seyfert-Margolis V, Krammer F, Rosen LB, Steen H, Syphurs C, Dandekar R, Shannon CP, Sekaly RP, Ehrlich LIR, Corry DB, Kheradmand F, Atkinson MA, Brakenridge SC, Higuita NIA, Metcalf JP, Hough CL, Messer WB, Pulendran B, Nadeau KC, Davis MM, Sesma AF, Simon V, van Bakel H, Kim-Schulze S, Hafler DA, Levy O, Kraft M, Bime C, Haddad EK, Calfee CS, Erle DJ, Langelier CR, Eckalbar W, Bosinger SE; IMPACC Network; Peters B, Kleinstein SH, Reed EF, Augustine AD, Diray-Arce J, Maecker HT, Altman MC, Montgomery RR, Becker PM, Rouphael N. Ozonoff A, et al. Nat Commun. 2024 Jan 3;15(1):216. doi: 10.1038/s41467-023-44090-5. Nat Commun. 2024. PMID: 38172101 Free PMC article.
58 results